Electrospray ionisation mass spectrometry facilitates detection of fibrinogen (Bβ14 Arg→Cys) mutation in a family with thrombosis

Thrombosis and Haemostasis

Volumn 78, Issue 6, 1997, Pages 1484-1487

  Brennan, Stephen O ^a   Hammonds, Bruce ^a   Spearing, Ruth ^a   George, Peter M ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BATROXOBIN; CYSTEINE; FIBRINOGEN; FIBRINOPEPTIDE B; LEUCINE; THROMBIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD CLOT; CASE REPORT; CONTROLLED STUDY; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; LUNG EMBOLISM; MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SPONTANEOUS ABORTION; THROMBOSIS;

EID: 0030668310     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1665438     Document Type: Article

References (13)

1. Smith RD, Loo JA, Edmonds CG, Barinaga CJ, Udseth HR. New developments in biochemical mass spectrometry: electrospray ionization. Anal Chem 1990; 62: 882-99.
2. Green BN, Jones AT, Roberts NB. Electrospray mass spectrometric evidence for the occurrence of two major variants in native pig pepsin A. Biochem J 1996; 313: 241-4.
3. Witkowska HE, Bitsch F, Shackleton CHL. Expediting rare variant hemoglobin characterization by combined HPLC/electrospray mass spectrometry. Hemoglobin 1993; 17: 227-42.
4. Brennan SO. Electrospray ionization analysis of human fibrinogen. Thromb Haemost 1997; 78: 1055-8.
5. Haverkate F, Samama M. Familial dysfibrinogenaemia and thrombophilia: Report on a study of the SSC subcommittee on fibrinogen. Thomb Haemost 1995; 73: 151-61.
6. Koopman J, Haverkate F, Grimbergen J, Engesser L, Novakova I, Krest AFJA, Lord ST. Abnormal fibrinogens IJmuiden (Bβ 14 Arg → Cys) and Nijmegen (Bβ 44 Arg → Cys) form disulfide-linked fibrinogen albumin complexes. Proc Natl Acad Sci USA 1992; 89: 3478-82.
7. Branson HE, Schmer G, Theodor I, Pirkle TH. Fibrinogen Seattle releases half the normal amount of fibrinopeptide B. Acta Haematol 1983; 79: 257-63.
8. Kaudewitz H, Henschen A, Soria C, Soria J, Bertrand O, Heaton D. The molecular defect of the genetically abnormal fibrinogen Christchurch II. In: Fibrinogen and its Derivatives. Muller-Berghaus G, Scheefers-Brochel V, Sellmayn E, Henschen A, eds. Elsevier Science Publishers BV 1986; pp 31-6.
9. Brennan SO, Hammonds B, George PM. Aberrant hepataic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (Aα 20 Val → Asp). J Clin Invest 1995; 96: 2854-8.
10. Henschen A, McDonagh J. Fibrinogen, fibrin and factor XIII. In: Blood Coagulation. Zwaal RFA, Hemker HC, eds. Elsevier Science Publishers Amsterdam BV 1986; pp 171-241.
11. Martinez J, Palascak J, Peters C. Functional and metabolic properties of human asialofibrinogen. J Lab Clin Med 1977; 89: 367-77.
12. Soria J, Soria C, Samama M, Poirot E, Kling C. Fibrinogen Troyes-fibrinogen Metz. Two new cases of congenital dysfibrinogenemia. Thromb Diath Haemorrh 1972; 27: 619-33.
13. al Mondhiry H, Ehmann WC. Congenital afibrinogenemia. Am J Hematol 1994; 46: 343-7.